6885.TW BRIM Biotechnology, Inc.

Healthcare Biotechnology Taiwan Stock Exchange
26.65 TWD
Close of Nov 6, 2026
20.05 34.65
Market cap
TWD 3.55B
P/E
-
P/B
2.30x
ROE
-23.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 6885.TW undervalued?

Graham number

The Graham number of BRIM Biotechnology, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

BRIM Biotechnology, Inc. fundamental analysis

No fundamental analysis for BRIM Biotechnology, Inc. yet.

BRIM Biotechnology, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About BRIM Biotechnology, Inc.

BRIM Biotechnology, Inc. engages in the research and development of drugs and therapies to combat and cure diseases in Taiwan. The company's lead product candidate is BRM421, a neurotrophic peptide which has completed a Phase 3 clinical trial for the treatment of dry eye disease. It is also developing BRM424, a treatment option that has completed Phase 1 clinical trial for neurotrophic keratitis; BRM411, a dual target inhibitor, which has completed Phase 2 clinical trial for…

Full company profile